Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) just unveiled an announcement.
Immunovia AB has announced the final terms of a Rights Issue, which is expected to raise approximately SEK 100 million before costs. The proceeds will be used to finance the commercial launch of PancreaSure and support additional studies for reimbursement in the U.S., potentially strengthening the company’s market position and stakeholder confidence.
More about Immunovia AB
Immunovia AB is a company operating in the biotechnology industry, focusing on the development and commercialization of diagnostic tests for complex diseases. Their primary product, PancreaSure, is aimed at early detection of pancreatic cancer, with a market focus on improving diagnostic accuracy and accessibility.
Average Trading Volume: 10,779,641
Technical Sentiment Signal: Sell
Current Market Cap: SEK153.7M
For detailed information about IMMNOV stock, go to TipRanks’ Stock Analysis page.